32 studies found for:    melanoma | Open Studies | interleukin-2
Show Display Options
Rank Status Study
21 Recruiting Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2
Condition: Metastatic Melanoma or Renal Cell Carcinoma
Intervention: Other: Boost of radiotherapy + high dose IL-2 treatment
22 Recruiting Study of Gene Modified Immune Cells in Patients With Advanced Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells;   Drug: non-myeloablative conditioning chemotherapy
23 Recruiting Fosaprepitant for Nausea and Vomiting During High-dose Interleukin-2 (HD IL-2) for Metastatic Melanoma and Renal Cell Carcinoma
Condition: Chemotherapy-induced Nausea and Vomiting
Intervention: Drug: Fosaprepitant
24 Recruiting High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: aldesleukin;   Biological: ipilimumab;   Other: laboratory biomarker analysis
25 Recruiting Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Aldesleukin;   Other: Laboratory Biomarker Analysis;   Biological: Ziv-Aflibercept
26 Unknown  The Role of Peptide-Loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2
Condition: Metastatic Melanoma
Intervention: Procedure: Immunotherapy treatment for melanoma
27 Recruiting Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
Condition: Metastatic Melanoma
Interventions: Drug: Ipilimumab;   Procedure: Tumor Infiltrating Lymphocytes (TIL);   Drug: Administration of Lymphodepletion;   Drug: Cyclophosphamide as Part of Lymphodepletion;   Drug: Fludarabine as Part of Lymphodepletion;   Drug: High Dose IL-2;   Biological: Adoptive Cell Therapy with TIL
28 Recruiting Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
Conditions: Recurrent Melanoma of the Skin;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Biological: Therapeutic Tumor Infiltrating Lymphocytes;   Biological: Aldesleukin;   Other: Laboratory Biomarker Analysis
29 Unknown  Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-Depleting Chemotherapy
Condition: Metastatic Melanoma
Intervention: Biological: tumor infiltrating lymphocytes
30 Recruiting Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma
Conditions: Desmoplastic Small Round Cell Tumor;   Disseminated Neuroblastoma;   Metastatic Childhood Soft Tissue Sarcoma;   Metastatic Ewing Sarcoma/PNET;   Metastatic Osteosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/PNET;   Recurrent Melanoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma
Interventions: Biological: IL-2;   Biological: GD2Bi-aATC;   Biological: GM-CSF;   Other: laboratory evaluations of immune responses
31 Recruiting Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2
Condition: Metastatic Malignant Melanoma and Renal Cell Carcinoma
Intervention: Biological: Irradiated donor lymphocyte infusion
32 Recruiting Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans
Condition: Cancer
Intervention: Biological: Bromelain and Comosain

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-32) Next Page   
Indicates status has not been verified in more than two years